Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA in Adult Participants Without HIV
NCT07390474
This study is recruiting at 7 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a phase 1, multicenter, open-label, dose escalation, first-in-human (FIH) trial to evaluate the safety and immunogenicity of DV201P-RNA and DV202B1-RNA, immunogens designed to induce HIV-1 envelope (Env) V2 apex-specific broadly neutralizing antibodies (V2 apex bnAbs). Both vaccines consist of a modified mRNA encapsulated in lipid nanoparticles (LNP) that when translated in cells produces HIV-1 Env gp150 transmembrane trimers. The trial will enroll adult volunteers without HIV and in overall good health.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- HIV
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Last updated on ClinicalTrials.gov
- August 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Georgia · 2
- The Ponce de Leon Center CRS (Site ID 5802) · Atlanta, GA
- The Hope Clinic of the Emory Vaccine Research Center; Emory University · Decatur, GA
Massachusetts · 1
- Beth Israel Deaconess Medical Center VCRS (BIDMC VCRS Site # 32077) · Boston, MA
New York · 2
- Columbia P&S CRS (Site ID: 30329) · New York, NY
- University of Rochester Vaccines to Prevent HIV Infection CRS (Site ID 31467) · Rochester, NY
Pennsylvania · 2
- Penn Prevention CRS (Site ID 30310) · Philadelphia, PA
- University of Pittsburgh CRS · Pittsburgh, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.